Clathrin Light Chain A/CLTA CRISPR Activation Plasmid (h): sc-403962-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Clathrin Light Chain A/CLTA CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Clathrin Light Chain A/CLTA CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Clathrin Light Chain A/CLTA CRISPR Activation Plasmid (h) and Clathrin Light Chain A/CLTA CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the CLTA transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Clathrin Light Chain A/CLTA CRISPR Activation Plasmid (h) | sc-403962-ACT | 20 µg | $397.00 |
CLTA encodes clathrin light chain A, a core accessory subunit of the clathrin coat that regulates assembly and dynamics of clathrin triskelions during clathrin-mediated endocytosis. By modulating coat stability and interactions with adaptor proteins, CLTA supports receptor internalization, synaptic vesicle recycling, and trafficking between the plasma membrane and endosomal compartments. These processes influence signaling turnover for growth factor receptors and nutrient transporters, linking CLTA function to pathways governing membrane homeostasis and intracellular sorting. Dysregulated endocytic trafficking and clathrin network perturbations are frequently studied in contexts such as neurobiology, infection biology, and oncogenic receptor signaling where altered uptake or recycling can reshape cellular behavior.
Clathrin Light Chain A/CLTA CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous CLTA expression without altering the underlying DNA sequence.
Clathrin Light Chain A/CLTA CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the CLTA locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the CLTA transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Clathrin Light Chain A/CLTA expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native CLTA locus and enabling the study of Clathrin Light Chain A/CLTA-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Clathrin Light Chain A/CLTA pathway restoration in tumor cells with silenced or reduced CLTA expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.